Condition: CMV Viremia · Heart Transplant Infection · Heart Transplant Failure and Rejection · Sponsor: Columbia University
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
This description comes directly from the study's public registry record.
Afsana Rahman, MD · 2123054600 · ar3262@cumc.columbia.edu
Adel T Alnatour, BS
Always discuss trial participation with your own doctor first.
| NYP-Weill Cornell | New York, New York, United States | Recruiting |
| Columbia University/NYP Milstein Hospital | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07079735